Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03745716
Title APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Aprea Therapeutics AB
Indications

myelodysplastic syndrome

Therapies

APR-246 + Azacitidine

Azacitidine

Age Groups: adult | senior
Covered Countries USA | FRA

Additional content available in CKB BOOST